Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...

That said, let's consider three stocks yielding well above 4% that income-oriented investors should consider: Pfizer (NYSE: ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Dividend investors are likely to find the stock's 6.7% yield attractive. That yield is the result of a 100% dividend payout ratio -- meaning the company devotes all its profit to the payments -- so ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...